Vivani Medical Inc (VANI) NPV
Vivani Medical, Inc. is a preclinical-stage biopharmaceutical company. The Company develops miniaturized and subdermal implants utilizing its NanoPortal technology to enable the delivery of a range of medicines to treat chronic diseases. It uses this platform technology to develop and commercialize drug implant candidates for the treatment of chronic disease and medication non-adherence. NanoPortal implant technology's initial focus is on peptide therapeutics for the treatment of patients with metabolic diseases. It operates through two segments: Biopharm Division and Neuromodulation Division. Its pipeline product candidates include NPM-119, NPM-159, NPM-139 and OKV-119. Its lead product, NPM-119, is a GLP-1 receptor agonist under development to treat patients with type two diabetes. NPM-159 is in feasibility testing for the treatment of non-alcoholic steatohepatitis (NASH). It is also in the development of neurostimulation systems to help patients recover critical body functions.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.